1. Home
  2. GANX vs ONMD Comparison

GANX vs ONMD Comparison

Compare GANX & ONMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GANX
  • ONMD
  • Stock Information
  • Founded
  • GANX 2017
  • ONMD 2006
  • Country
  • GANX United States
  • ONMD United States
  • Employees
  • GANX N/A
  • ONMD N/A
  • Industry
  • GANX Biotechnology: Pharmaceutical Preparations
  • ONMD
  • Sector
  • GANX Health Care
  • ONMD
  • Exchange
  • GANX Nasdaq
  • ONMD Nasdaq
  • Market Cap
  • GANX 79.8M
  • ONMD 71.4M
  • IPO Year
  • GANX 2021
  • ONMD N/A
  • Fundamental
  • Price
  • GANX $2.80
  • ONMD $1.38
  • Analyst Decision
  • GANX Strong Buy
  • ONMD
  • Analyst Count
  • GANX 6
  • ONMD 0
  • Target Price
  • GANX $8.00
  • ONMD N/A
  • AVG Volume (30 Days)
  • GANX 1.2M
  • ONMD 785.3K
  • Earning Date
  • GANX 11-12-2025
  • ONMD 11-14-2025
  • Dividend Yield
  • GANX N/A
  • ONMD N/A
  • EPS Growth
  • GANX N/A
  • ONMD N/A
  • EPS
  • GANX N/A
  • ONMD N/A
  • Revenue
  • GANX N/A
  • ONMD $494,000.00
  • Revenue This Year
  • GANX N/A
  • ONMD N/A
  • Revenue Next Year
  • GANX N/A
  • ONMD N/A
  • P/E Ratio
  • GANX N/A
  • ONMD N/A
  • Revenue Growth
  • GANX N/A
  • ONMD N/A
  • 52 Week Low
  • GANX $1.41
  • ONMD $0.30
  • 52 Week High
  • GANX $3.06
  • ONMD $4.22
  • Technical
  • Relative Strength Index (RSI)
  • GANX 62.34
  • ONMD 41.93
  • Support Level
  • GANX $2.60
  • ONMD $1.04
  • Resistance Level
  • GANX $3.05
  • ONMD $1.52
  • Average True Range (ATR)
  • GANX 0.28
  • ONMD 0.17
  • MACD
  • GANX 0.03
  • ONMD -0.04
  • Stochastic Oscillator
  • GANX 79.78
  • ONMD 42.49

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.

About ONMD OneMedNet Corp

OneMedNet Corp is a healthcare software company with solutions focused on digital medical image management, exchange, and sharing. It is a provider of clinical imaging innovation and curator of regulatory-grade Imaging Real World Data(iRWDTM). Its solutions connect healthcare providers and patients, satisfying a crucial need within the life sciences field, offering direct access to clinical images and the associated contextual patient record. OneMedNet's technology has provens the commercial and regulatory viability of imaging Real World Data (as defined below), an emerging market, and provides regulatory-grade, image-centric iRWDTM that exactly matches OneMedNet's life science partners' case selection protocols, paving the way for Real World Evidence.

Share on Social Networks: